Phase Ib Trial of Combination Immunotherapy With HER2/Neu Peptide GP2 + GM-CSF Vaccine and Trastuzumab in Breast Cancer Patients
Latest Information Update: 07 Nov 2021
Price :
$35 *
At a glance
- Drugs HER2/Neu GP2 vaccine Greenwich LifeSciences Inc/NuGenerex Immuno-Oncology (Primary) ; Trastuzumab
- Indications Breast cancer
- Focus Adverse reactions
- 08 May 2013 Status changed from recruiting to active, no longer recruiting as reported by M.D. Anderson Cancer Center.
- 01 Mar 2012 New trial record